| 货号 | MAB1310-SP |
| 别名 | ATF; EC 3.4.21; EC 3.4.21.73; plasminogen activator, urokinase; PLAU; uPA; u-PA; U-plasminogen activator; urinary; Urokinase; urokinase-type plasminogen activator | 全称 | Urokinase-type Plasminogen Activator |
| 反应种属 | Human |
| 应用 | Western Blot,Immunoprecipitation,ELISA Capture (Matched Antibody Pair),ELISA Detection (Matched Antibody Pair),ELISA Standard |
| 目标/特异性 | Detects human u-Plasminogen Activator (uPA)/Urokinase Catalytic Domain in direct ELISAs and Western blots. In Western blots under reducing conditions, it reacts with the catalytic domain (B chain) only. In Western blots under non-reducing conditions, it reacts with the B chain and disulfide bond-linked B and A chains. In direct ELISAs, no cross-reactivity with recombinant human (rh) Factor X, rhHGFA, rhKLK‑3, -4, -5, -6, -8, -10, -11, rhThrombin, or recombinant mouse WIF-1 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Immunoprecipitation: 25 µg/mL ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : |
| 来源 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 5328 (Human); 18792 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human u-Plasminogen Activator (uPA)/Urokinase Catalytic Domain Ser21-Leu431 Accession # P00749 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium (2). For example, the combination (both low vs. either or both high) of uPA and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), outperforms the single factors as well as other traditional prognostic factors with regard to risk group assessment for breast cancer, particularly in node-negative breast cancer (3). The human uPA is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues) (4‑6). The single chain molecule is processed into a disulfide-linked two-chain molecule. The B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). The resulting two-chain forms have different molecular weights (MW). The B chain is common for both forms whereas the long and short A chains are unique to the high and low MW forms, respectively. The long A chain contains an EGF-like domain, which is responsible for binding of the uPA receptor (uPAR). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|